查詢結果分析
相關文獻
- Comparisons between Allogeneic Peripheral Blood Stem Cell Transplantation and Allogeneic Bone Marrow Transplantation in Adult Hematologic Disease: A Single Center Experience
- 骨髓移植的另一突破--非親屬間之異體移植
- 接受異體週邊血液幹細胞移植個案之護理經驗
- 世界各國臍帶血銀行之設立狀況
- Transplantation for Adrenoleukodystrophy with HLA-A and B Nonidentical Paternal Marrow: Report of One Case
- 脫鈣冷凍乾燥異體移植骨於骨再生方面的效果
- 造血幹細胞移植的演進
- 非親屬骨髓移植
- Bone Marrow Cryopreservation and Clinical Implications in Autologous Bone Marrow Transplantation
- 海洋性貧血患童ABO 血型不合之異體骨髓移植
頁籤選單縮合
題 名 | Comparisons between Allogeneic Peripheral Blood Stem Cell Transplantation and Allogeneic Bone Marrow Transplantation in Adult Hematologic Disease: A Single Center Experience=異體週邊血液幹細胞移植與骨髓移植於成年人血液疾病之比較--某醫學中心之經驗 |
---|---|
作 者 | 劉益昌; 張肇松; 劉大智; 陳田柏; 蘇裕傑; 蕭惠樺; 林勝豐; | 書刊名 | The Kaohsiung Journal of Medical Sciences |
卷 期 | 19:11 2003.11[民92.11] |
頁 次 | 頁541-548 |
分類號 | 416.292 |
關鍵詞 | 異體移植; 骨髓移植; 週邊血液幹細胞移植; Allogeneic; Bone marrow transplantation; Peripheral blood stem cell transplantation; |
語 文 | 英文(English) |
中文摘要 | 這篇回溯性研究比較 32 位不同血液疾病病患,包括急性骨髓性白血病,急性淋巴性白血病,慢性骨髓性白血病,骨髓分化不良症候群睿再生不良性貧血,接受組織抗原相配合親屬間異體骨髓移植 (BMT) 或異體週邊血液幹細胞移植 (PBSCT) 之結果。其中 BMT 14 例,PBSCT 18 例,中位追蹤期為 58 及 18 個月。PBSCT 相較於 BMT 表現出較快嗜中性球植入 (中位數 8 及 13 天,p < 0.001) 和血小板植入 (中位數 9 及 17 天,p < 0.001),也顯示較少血小板輸注 (中位數 54 及 144 單位,p < 0.001),但紅血球輸注則無差異。移植 100 天內急性移植物反宿主病 (GVHD) 及二至四級 GVHD 兩組間並無差異 (42.9% 及 33.3%,p = 0.72;14.3% 及 5.6%,p = 0.57),慢性 GVHD 發生率也無差異 (20% 及 33.3%,p = 0.67)。所有復發病人 (BMT 5 位,PBSCT 3 位) 無人表現慢性 GVHD,且所有表現慢性 GVHD 者並無人復發。疾病復發均為最常見的死因 (佔 BMT 55.6%,PBSCT 75%,p = 0.25),大多發生於移植一年內。整體存活以 PBSCT 較佳 (35.7% 及 77.8%,p = 0.029),若只考慮血液惡性疾病即無差異 (30.8% 及 63.6%,p = 0.20)。這些分析和其它研究相似,且 PBSCT 表現出更快的嗜中性球及血小板植入,和較少嚴重型急性及廣泛型慢性 GVHD。這顯示PBSCT 在成年人血液疾病是一種可行且較為有利的選擇。 |
英文摘要 | This retrospective study compared the outcomes in 32 adult patients with hematologic diseases (acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, myelodysplastic syndrome, severe aplastic anemia) who received allogeneic bone marrow transplantation (BMT, n = 14; median age, 28 years) or allogeneic peripheral blood stem cell transplantation (PBSCT, n = 18; median age, 29 years) from human leukocyte antigen-identical sibling donors. Median follow-up was 58 months in BMT recipients and 18 months in PBSCT recipients. Neutrophil (median, Day 8 vs Day 13, p < 0.001) and platelet engraftment (median, Day 9 vs Day 17, p < 0.001) was faster in the PBSCT group than in the BMT group. Patients receiving PBSCT required less platelet transfusion than those receiving BMT (median, 54 units vs 144 units, p < 0.001), but there was no significant difference in red cell transfusion. At 100 days, there was no difference in the incidence of acute graft-versus-host disease (GVHD) (42.9% vs 33.3%, p = 0.72) or grade II-IV acute GVHD (14.3% vs 5.6%, p = 0.57), and there was no difference in the cumulative incidence of chronic GVHD (20% vs 33.3%, p = 0.67). No chronic GVHD was noted in any relapsed patients (BMT, 5; PBSCT, 3), and no patients with chronic GVHD during follow-up had a relapse. Relapse was the most frequent cause of death in both groups (BMT, 5/9, 55.6%; PBSCT, 3/4, 75%; p = 0.25); all relapses occurred within 1 year after transplantation. Overall survival was significantly better in the PBSCT group (35.7% vs 77.8%, p = 0.029), but this difference was lost if only hematologic malignancies were analyzed (30.8% vs 63.6%, p = 0.20). Our results are similar to those reported previously, with faster neutrophil and platelet engraftment and less severe acute GVHD and extensive chronic GVHD with PBSCT. Allogeneic PBSCT is a feasible and beneficial alternative to allogeneic BMT in adult hematologic disease. |
本系統中英文摘要資訊取自各篇刊載內容。